Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Business Wire

28 Jul 2026, 11:45 UTC · 5h ago

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

Read original · https://www.businesswire.com/news/home/20260728012034/en/Lantern-Pharma-to-Advance-EMA-Cleared-Phase-1b2-Trial-of-LP-184-Zirdafulven-in-Biomarker-Selected-Advanced-Bladder-Cancer/

Free · No account

Track these names every morning.

Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.

We’ll watch

#biotech#clinical_trial#drug_development#phase_1b

Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.

Free forever · one email a day, max · unsubscribe in one click.How it works

How the impact breaks down

Where the story's weight lands

Impact by category

Market Behaviour+0.300
Sector Rotation+0.200

Biggest drivers

Short Squeeze Potential+0.300

6 related stories

Seeking Alpha
1d ago
Eledon: At The Center Of The Next Medical Frontier
- biotech
- phase 2
Read

Lantern Pharma to Advance EMA-Cleared… | NewsImpactScreener

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

Track these names every morning.

Impact by category

Biggest drivers

Eledon: At The Center Of The Next Medical Frontier

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

Track these names every morning.

Impact by category

Biggest drivers

Eledon: At The Center Of The Next Medical Frontier

Most positively impacted

Most negatively impacted

Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect?

EQUITY ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

AstraZeneca's drug pipeine is splitting opinion among City analysts

Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial

Allergy Therapeutics names Helge Weiner-Trapness as executive chair

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

Track these names every morning.

Impact by category

Biggest drivers

Next reads from the same story arc

Eledon: At The Center Of The Next Medical Frontier

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

Track these names every morning.

Impact by category

Biggest drivers

Next reads from the same story arc

Eledon: At The Center Of The Next Medical Frontier

Most positively impacted

Most negatively impacted

Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect?

EQUITY ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026

AstraZeneca's drug pipeine is splitting opinion among City analysts

Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial

Allergy Therapeutics names Helge Weiner-Trapness as executive chair